Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06516978
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-18
Brief Title:
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Prospective Open-Label Multicenter Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin Rituximab Cyclophosphamide Doxorubicin and Prednisone Combined With OrelabrutinibChidamideVenetoclaxLenalidomidePD1 Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to compare the efficacy and safety of Polatuzumab Vedotin Rituximab Cyclophosphamide Doxorubicin and Prednisone combined with OrelabrutinibChidamideVenetoclaxLenalidomidePD1 Pola-RCHP-X versus RCHOP-X and Pola-RCHP in previously untreated patients with DLBCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None